Apply for Firazyr (Icatibant) Copay Assistance & Patient Savings Programs

Yes. QuickRx Specialty Pharmacy offers completely free enrollment support for Firazyr copay assistance programs. We don’t charge application fees or service charges—our mission is to help you access affordable treatment for hereditary angioedema (HAE) attacks.

What’s included at no cost:

• Complete application assistance for copay cards and financial aid programs
• Insurance benefit verification and coverage analysis
• Prior authorization coordination when required
• Continuous benefit monitoring to maintain your savings
• Temperature-controlled home delivery coordination
• Self-injection training and support

Firazyr savings programs available:

For commercially insured patients: Manufacturer copay cards can dramatically reduce your prescription costs, with many eligible patients paying $0 regardless of your plan’s usual cost-sharing requirements.

For Medicare and Medicaid patients: Independent foundation grant programs offer financial assistance to help cover medication expenses. These nonprofit programs are free to apply for, and QuickRx guides you through the entire process.

For uninsured or underinsured patients: Patient assistance programs may provide Firazyr at no cost or significantly reduced prices based on household income and medical necessity.

QuickRx’s specialty pharmacy team works exclusively to eliminate financial barriers to your HAE treatment, allowing you to focus on your health.

Eligibility depends on your insurance type, medical diagnosis, and financial circumstances. Here’s how QuickRx makes enrollment simple:

Step 1: Reach out to QuickRx
Call (917) 830-2525 or toll-free (800) 496-6111, or complete our confidential online enrollment form.

Step 2: Insurance verification
Our team verifies your prescription coverage and identifies which Firazyr copay assistance programs you qualify for based on your insurance type.

Step 3: Program enrollment
We handle all enrollment paperwork for manufacturer copay cards, patient assistance programs, or foundation grants—completely free of charge.

Step 4: Ongoing support
QuickRx monitors your benefits, handles prescription refills, and ensures your savings continue uninterrupted.

General eligibility requirements:

• Valid prescription for Firazyr (icatibant) for hereditary angioedema attacks
• U.S. residency
• Commercial insurance, Medicare, Medicaid, or uninsured status
• Financial need (for some programs)

Most patients qualify for at least one form of Firazyr financial assistance. Contact QuickRx today to learn which programs you’re eligible for.

Firazyr is a costly specialty medication, but with QuickRx’s copay assistance coordination, eligible patients may pay as little as $0 per treatment depending on their insurance type and financial situation.

How copay assistance works by insurance type:

Commercial Insurance:
• Eligible patients with manufacturer copay cards may pay $0
• Copay cards help cover coinsurance and deductibles
• No income restrictions or complex applications

Medicare Part D:
• Foundation grants available for eligible patients to cover deductibles, coinsurance, and copays
• Income-based eligibility (varies by foundation)
• Renewable grants every 3-12 months
• Many eligible patients pay $0 with grant assistance

Medicaid:
• Foundation grants available to cover any state-required copays or cost-sharing
• Income-based eligibility
• Eligible patients often pay $0

No Insurance:
• Patient assistance programs may provide free medication to eligible patients
• Income limits typically 400-500% of federal poverty level
• Annual application required

The exact amount you’ll pay depends on your specific insurance plan, chosen assistance programs, and eligibility. QuickRx provides a personalized cost estimate before your first Firazyr order—you’ll know your exact out-of-pocket cost before committing.

Yes. Medicare patients cannot use manufacturer copay cards due to federal anti-kickback regulations, but QuickRx connects Medicare beneficiaries to independent charitable foundations that provide grants to help cover Firazyr costs.

How foundation grants work for Medicare patients:

Step 1: QuickRx identifies foundation programs covering hereditary angioedema medications.

Step 2: We complete the grant application on your behalf (free service).

Step 3: Once approved, the foundation sends grant funds directly to your Medicare Part D plan or specialty pharmacy.

Step 4: Your out-of-pocket costs are reduced or eliminated for the grant period (typically 3-12 months).

Grant eligibility factors:
• Household income (varies by foundation)
• Medicare Part D enrollment
• Firazyr prescription for hereditary angioedema
• U.S. residency

Many Medicare patients qualify for foundation grants that reduce their Firazyr costs to $0. QuickRx will assess your eligibility and handle all grant applications free of charge.

Contact QuickRx at (917) 830-2525 or (800) 496-6111 to explore Medicare copay assistance options.

If you’re struggling to afford Firazyr, QuickRx Specialty Pharmacy will work with you to find a solution. We specialize in patient assistance programs that provide free or low-cost medication to eligible patients.

Options when you can’t afford Firazyr:

1. Patient Assistance Programs (PAPs)
Manufacturer-sponsored programs that provide free Firazyr to uninsured or underinsured patients who meet income requirements (typically 400-500% of federal poverty level).

2. Foundation Grants
Independent charitable organizations that provide financial assistance for hereditary angioedema medications regardless of insurance status.

3. Medicare Extra Help / Low-Income Subsidy (LIS)
Federal program that helps Medicare beneficiaries with limited income and resources pay for prescription drugs.

4. State Pharmaceutical Assistance Programs (SPAPs)
Some states offer additional drug coverage programs for residents who qualify.

QuickRx’s role:
We assess your situation, identify all available assistance programs, complete applications on your behalf, and advocate for approvals—all at no cost to you.

Don’t go without treatment. Contact QuickRx at (917) 830-2525 or (800) 496-6111 to explore financial assistance options today.

Firazyr (icatibant) is a prescription medication used to treat acute attacks of hereditary angioedema (HAE) in adults and adolescents.

What is hereditary angioedema?

HAE is a rare genetic disorder that causes sudden, severe swelling (angioedema) in various parts of the body, including:
• Face, lips, tongue, or throat
• Hands, feet, or genitals
• Abdomen (causing severe pain, nausea, vomiting)

HAE attacks can be life-threatening when swelling occurs in the throat or larynx (voice box), potentially blocking the airway.

How Firazyr works:

Firazyr is a selective bradykinin B2 receptor antagonist. During HAE attacks, the body produces excess bradykinin, which causes blood vessels to leak fluid into surrounding tissues, resulting in swelling. Firazyr blocks bradykinin from binding to its receptors, reducing swelling, inflammation, and pain during acute attacks.

FDA-approved uses:
• Treatment of acute HAE attacks in adults
• Treatment of acute HAE attacks in adolescents (limited data for ages ≥2 years)

Important: Firazyr treats acute attacks but does NOT prevent future HAE attacks. Separate preventive therapies may be prescribed by your doctor to reduce attack frequency.

For medical information about hereditary angioedema, visit US Hereditary Angioedema Association (HAEA).

Firazyr is given as a subcutaneous injection (a shot into the fatty tissue under the skin) in the abdomen area.

Administration details:

Dosing:
• Adults: 30 mg given as a single injection at the onset of an HAE attack
• May repeat every 6 hours if symptoms return or are inadequate
• Maximum dose: 90 mg per 24 hours (3 doses)

Injection site:
• Inject 2 to 4 inches below the belly button on either side
• Do NOT inject within 2 inches of a scar
• Do NOT inject into skin that is bruised, swollen, or painful

Self-administration:
Patients may self-administer Firazyr upon recognition of an HAE attack after proper training by a healthcare provider. QuickRx provides injection training and support for patients who prefer to keep Firazyr at home for emergency use.

Injection technique:
1. Wash hands thoroughly
2. Check solution—do not use if cloudy, leaking, discolored, or contains particles
3. Remove cap from prefilled syringe
4. Pinch skin and insert needle at 45-90 degree angle
5. Inject over ≥30 seconds
6. Dispose of used syringe in sharps container

Each prefilled syringe is for one use only. Do not reuse needles or syringes.

Important safety note: If you use Firazyr for swelling in your neck or throat, go to the emergency room immediately after using it, as airway obstruction may occur during acute laryngeal attacks.

For administration guidance, refer to FDA medication guides.

Like all medications, Firazyr can cause side effects. Most side effects are mild, but some may require medical attention.

Very common side effects (>10% of patients):
• Injection site reactions (97%): Pain, redness, swelling, bruising, itching, or warmth where the shot was given

Common side effects (1-10% of patients):
• Dizziness or headache (3%)
• Increased liver enzymes (4%)
• Fever (4%)
• Nausea
• Feeling sleepy

Rare but serious side effects:

Allergic reactions: Seek immediate medical help if you experience:
• Rash, hives, or itching
• Red, swollen, blistered, or peeling skin
• Wheezing or tightness in the chest or throat
• Trouble breathing, swallowing, or talking
• Unusual hoarseness
• Swelling of the mouth, face, lips, tongue, or throat

Airway obstruction: If Firazyr is used for swelling in your neck or throat, go to the ER right away after using it, as HAE attacks affecting the larynx (voice box) can rapidly block the airway.

Drug interactions:
Firazyr may decrease the effects of ACE inhibitors (blood pressure medications). Discuss all medications with your doctor.

When to call your doctor:
• Injection site reactions that worsen or don’t go away
• Persistent dizziness or headache
• Signs of allergic reaction
• Any side effects that concern you

For comprehensive side effect information, visit MedlinePlus drug information.

Before using Firazyr, tell your doctor about all your medical conditions and medications to ensure safe treatment.

Tell your doctor if you:

• Are allergic to icatibant or any ingredients in Firazyr
• Are pregnant, planning to become pregnant, or breastfeeding (limited data available on use during pregnancy)
• Are taking ACE inhibitors (blood pressure medications)—Firazyr may reduce their effectiveness
• Have a history of stroke or heart problems
• Have liver or kidney disease

Medications to discuss:

Tell your doctor and pharmacist about all medications you take, including:
• Prescription medications
• Over-the-counter drugs
• Vitamins and supplements
• Herbal products

ACE inhibitors interaction: Firazyr may decrease antihypertensive effects of ACE inhibitors (commonly prescribed for high blood pressure or heart failure). Your doctor will monitor this interaction.

Pregnancy and breastfeeding:

• Pregnancy: Limited data on Firazyr use during pregnancy. When HAE treatment is needed during pregnancy, other agents are generally recommended. Discuss risks and benefits with your doctor.
• Breastfeeding: It’s unknown if icatibant passes into breast milk. Discuss with your doctor whether to breastfeed during Firazyr treatment.

Driving and alertness:
Firazyr may cause dizziness or drowsiness. Avoid driving or operating machinery until you know how this medication affects you.

Your doctor needs complete information to prescribe Firazyr safely. For medical guidance, consult resources like UpToDate.

Follow these important precautions when using Firazyr to ensure safe and effective treatment of hereditary angioedema attacks.

Critical precautions:

1. Laryngeal (throat) attacks:
If you use Firazyr for swelling in your neck or throat, go to the emergency room immediately after injection. Airway obstruction may occur during acute laryngeal HAE attacks and requires immediate medical supervision.

2. Limit daily dosing:
Do NOT use more than 3 doses (90 mg total) in a 24-hour period.

3. Storage:
• Store at room temperature (68-77°F/20-25°C) or in refrigerator (36-46°F/2-8°C)
• Do NOT freeze
• Store in original container until time of use
• Keep out of reach of children

4. Inspect before use:
Do not use if the solution is:
• Cloudy
• Leaking
• Contains particles
• Has changed color

5. Proper disposal:
• Each prefilled syringe is for ONE USE ONLY
• Dispose of used needles and syringes in a sharps disposal container
• Follow local regulations for sharps disposal

6. Injection site care:
• Rotate injection sites
• Do not inject into bruised, swollen, painful, or scarred skin
• Stay at least 2 inches away from previous injection sites

7. Emergency preparedness:
• Tell all healthcare providers that you take Firazyr for HAE
• Carry medical identification indicating you have hereditary angioedema
• Know the signs of severe allergic reactions

8. Monitoring:
Your doctor should monitor you for:
• Symptom relief after injection
• Airway symptoms (if throat swelling occurs)
• Adverse reactions at injection sites

For HAE emergency preparedness, visit US Hereditary Angioedema Association.

Hereditary angioedema (HAE) is a rare genetic disorder that causes recurrent episodes of severe swelling (angioedema) in various parts of the body.

What causes HAE?

HAE is caused by a genetic mutation that leads to:
• Deficiency of C1-esterase inhibitor (C1-INH) (Type I HAE—most common)
• Dysfunction of C1-esterase inhibitor (Type II HAE)
• Normal C1-INH but other genetic mutations (Type III HAE—rare)

Without functioning C1-INH, the body produces excess bradykinin during attacks, causing blood vessels to leak fluid into surrounding tissues, resulting in swelling.

HAE attack symptoms:

Swelling can occur in:
• Skin: Face, lips, tongue, hands, feet, genitals
• Gastrointestinal tract: Severe abdominal pain, nausea, vomiting, diarrhea (often mistaken for appendicitis)
• Airway: Throat, tongue, larynx (voice box)—can be life-threatening

Attack triggers:
• Stress or anxiety
• Minor trauma or surgery
• Infections
• Menstruation
• Certain medications (e.g., ACE inhibitors)
• Often, attacks occur without an identifiable trigger

HAE characteristics:
• Attacks typically last 2-5 days if untreated
• Frequency varies from weekly to once per year
• Swelling is usually NOT itchy (unlike allergic reactions)
• Does NOT respond to antihistamines, corticosteroids, or epinephrine

Diagnosis:
HAE is diagnosed through:
• Family history (inherited in autosomal dominant pattern)
• Blood tests measuring C4, C1-INH levels, and C1-INH function
• Genetic testing

HAE treatment approaches:
• Acute treatment: Medications like Firazyr (icatibant) to stop attacks in progress
• Prophylactic treatment: Daily medications to prevent attacks
• Emergency preparedness: Access to on-demand treatments

For comprehensive HAE information, visit the US Hereditary Angioedema Association (HAEA)

Firazyr begins working quickly after injection to relieve hereditary angioedema (HAE) attack symptoms.

Onset of action:
• Median time to 50% symptom reduction: Approximately 2 hours after injection
• Duration of effect: Inhibits bradykinin-caused symptoms for approximately 6 hours

What to expect after Firazyr injection:

First 2 hours:
Most patients begin experiencing symptom relief within 2 hours. Swelling, pain, and discomfort gradually decrease.

2-6 hours:
Symptoms continue to improve as Firazyr blocks bradykinin receptors.

After 6 hours:
If symptoms return or were not adequately controlled, a second dose may be given. You can receive up to 3 doses (90 mg total) within 24 hours.

When to seek medical help:

• If symptoms worsen despite Firazyr treatment
• If swelling affects your throat or airway (go to ER immediately)
• If you’ve used 3 doses without adequate relief
• If you experience signs of allergic reaction

Important: Firazyr treats acute HAE attacks but does NOT prevent future attacks. Talk to your doctor about preventive (prophylactic) therapies if you experience frequent HAE attacks.

Self-administration benefits:
Keeping Firazyr at home allows you to treat attacks immediately upon onset, which may lead to faster symptom resolution compared to delayed treatment.

For HAE attack management strategies, consult with your specialist or visit HAEA resources.

There are no known direct interactions between Firazyr (icatibant) and alcohol. However, consider these factors:

Alcohol and HAE attacks:

While alcohol is not a documented trigger for hereditary angioedema attacks in most patients, individual triggers vary. Some patients report that alcohol may trigger or worsen their HAE symptoms.

Alcohol and medication side effects:

Firazyr may cause:
• Dizziness
• Drowsiness
• Headache

Alcohol can worsen these side effects, potentially impairing your coordination, alertness, and judgment.

Recommendations:

• During an HAE attack: Avoid alcohol while experiencing symptoms or immediately after using Firazyr
• After Firazyr injection: Wait until side effects (dizziness, drowsiness) have resolved before drinking alcohol
• Know your triggers: Track whether alcohol consumption precedes your HAE attacks

General guidance:

If you choose to drink alcohol:
• Drink in moderation
• Avoid drinking if you feel dizzy or drowsy from Firazyr
• Do not drive or operate machinery if you’ve had alcohol or are experiencing Firazyr side effects

Discuss with your doctor:
Talk to your healthcare provider about alcohol consumption and whether it may affect your hereditary angioedema management.

For lifestyle management tips for HAE patients, visit HAEA patient resources.

Proper storage of Firazyr ensures the medication remains effective when you need it during a hereditary angioedema attack.

Storage temperature:

Firazyr can be stored at:
• Room temperature: 68-77°F (20-25°C)
• Refrigerated: 36-46°F (2-8°C)

Do NOT freeze Firazyr. Freezing may damage the medication.

Storage guidelines:

• Original container: Store in original container until time of administration
• Protect from light: Keep in the original packaging to protect from light exposure
• Avoid extreme temperatures: Do not store near heat sources or in direct sunlight

Shelf life:

Check the expiration date printed on the carton and syringe. Do not use Firazyr after the expiration date.

Traveling with Firazyr:

If you travel with Firazyr:
• Keep in carry-on luggage (do not check)
• Use insulated travel case if needed to maintain appropriate temperature
• Carry a letter from your doctor explaining your need for injectable medication
• Check TSA guidelines for traveling with syringes

Inspection before use:

Before each injection, inspect the solution:
• Do NOT use if:
– Solution is cloudy
– Solution has changed color
– Container is leaking
– Particles are visible

After opening:

Each prefilled syringe is for single use only. Once opened, use immediately and discard any unused portion.

Disposal:

Dispose of used syringes in a sharps container according to local regulations. Do not throw in regular trash.

For medication storage best practices, refer to FDA guidelines.

The use of Firazyr during pregnancy and breastfeeding requires careful consideration and discussion with your healthcare provider.

Pregnancy:

• Limited data available: There is limited outcome data following maternal administration of icatibant during pregnancy.

• Current recommendations: When treatment for acute hereditary angioedema attacks in pregnancy is needed, agents other than icatibant are generally recommended.

• Monitoring required: Patients with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery.

• FDA Pregnancy Category: The risk-benefit assessment should be made on an individual basis by your healthcare provider.

If you’re pregnant or planning to become pregnant:
• Tell your doctor immediately
• Discuss alternative HAE treatments that may be safer during pregnancy
• Your doctor will weigh the risks and benefits for your specific situation

Breastfeeding:

• Unknown excretion: It is not known if icatibant is present in breast milk.
• Minimal systemic absorption expected: According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.

Lactation considerations:

Lactation may increase the frequency of hereditary angioedema attacks. When treatment for acute HAE attacks in lactating patients is needed, agents other than icatibant are generally recommended.

Important:

• Do NOT use Firazyr during pregnancy or breastfeeding without discussing with your doctor first
• Your healthcare provider will help you develop a safe HAE management plan during pregnancy and postpartum

For pregnancy and HAE management, consult specialists or visit HAEA pregnancy resources.

Firazyr (icatibant) is one of several FDA-approved treatments for hereditary angioedema, each with different mechanisms of action and uses.

HAE treatment categories:

1. Acute attack treatments (on-demand):

These medications are used during an attack to stop symptoms:

• Firazyr (icatibant):
– Bradykinin B2 receptor antagonist
– Subcutaneous self-injection
– Works in ~2 hours
– Can be kept at home for immediate use

• Other acute treatments:
– C1-esterase inhibitor concentrates: Replace the missing or dysfunctional protein
– Kallikrein inhibitors: Block production of bradykinin

2. Prophylactic (preventive) treatments:

These medications are taken regularly to prevent future attacks:

• Daily or twice-weekly medications
• Reduce attack frequency and severity
• Different mechanism than acute treatments

3. Short-term prophylaxis:

Used before dental procedures, surgery, or other triggers to prevent attacks.

Why Firazyr may be prescribed:

• Self-administration: Can be given at home without IV access
• Mechanism of action: Directly blocks bradykinin receptors
• Fast-acting: Rapid symptom relief
• Portability: Can be carried for emergency use

Treatment choice factors:

Your doctor will recommend HAE treatment based on:
• Attack frequency and severity
• Your ability to self-administer
• Insurance coverage and cost
• Personal preference
• Medical history

Important: Firazyr treats acute attacks but does NOT prevent future attacks. Many HAE patients use both acute and prophylactic therapies as part of a comprehensive management plan.

For HAE treatment comparisons and options, visit HAEA treatment information.

1. Betschel S, Badiou J, Binkley K, et al. The international/Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2019;15:72. doi:10.1186/s13223-019-0376-8. PubMed
2. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150. doi:10.1016/j.jaip.2020.08.046. PubMed
3. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update. World Allergy Organ J. 2022;15(3):100627. doi:10.1016/j.waojou.2022.100627. PubMed
4. Cicardi M, Banerji A, Bracho F, et al. Icatibant, A New Bradykinin-Receptor Antagonist in Hereditary Angioedema. N Engl J Med. 2010;363(6):532-541. doi:10.1056/NEJMoa0906393. PubMed
5. Baş M, Greve J, Stelter K, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015;372(5):418-425. doi:10.1056/NEJMoa1312524. PubMed
6. Farkas H, Kőhalmi KV, Veszeli N, et al. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. J Allergy Clin Immunol Pract. 2017;5(6):1671-1678. doi:10.1016/j.jaip.2017.04.010. PubMed
7. Boufleur K, Delcaro L, Cordeiro DL, et al. Successful and safe use of icatibant for life-threatening angioedema attack during pregnancy in a patient with hereditary angioedema type I. J Allergy Clin Immunol. 2014;133(2 suppl):AB36. doi:10.1016/j.jaci.2013.12.153
8. Craig T, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012;5(12):182-199. doi:10.1097/WOX.0b013e318279affa. PubMed
9. National Organization for Rare Disorders (NORD). Hereditary Angioedema. Accessed November 2025.
10. US Hereditary Angioedema Association (HAEA). Patient Resources and Treatment Information. Accessed November 2025.
11. Firazyr (icatibant) [prescribing information]. Cambridge, MA: Takeda Pharmaceuticals America Inc; June 2025.
12. U.S. Food and Drug Administration. Medication Guides and Safety Information. Accessed November 2025.

—

Disclaimer:

This information is provided for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. The content on this page is based on published medical literature, FDA-approved prescribing information, and clinical guidelines for hereditary angioedema management.

QuickRx Specialty Pharmacy is an independent pharmacy that provides copay assistance enrollment services and does not diagnose, treat, or prescribe medications. All treatment decisions should be made in consultation with a qualified healthcare provider who is familiar with your individual medical history and current health status.

The information presented here does not constitute medical advice and should not be used as a substitute for consultation with qualified healthcare professionals. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition, medication, or treatment options.

Copay assistance program eligibility, savings amounts, and availability are subject to change and may vary based on insurance coverage, medication, and individual circumstances. QuickRx makes no guarantees regarding program acceptance, benefit amounts, or continued availability of assistance programs.

QuickRx Specialty Pharmacy is an independent pharmacy and is not affiliated with, endorsed by, or sponsored by Takeda Pharmaceuticals America Inc., the manufacturer of Firazyr, or any other pharmaceutical manufacturer. Brand names mentioned on this page are the property of their respective owners and are used for informational purposes only.

If you are experiencing a medical emergency or life-threatening hereditary angioedema attack affecting your airway, call 911 or go to the nearest emergency room immediately.

Last updated: November 2025